Great Point Partners’s Tempest Therapeutics TPST Stock Holding History

Great Point Partners’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,385	Closed	-$578K	–	37
2020 Q4	$578K	Sell	1,385 -4,656	-77%	-$1.61M	0.09%	33
2020 Q3	$1.92M	Sell	6,041 -1,450	-19%	-$492K	0.17%	33
2020 Q2	$2.57M	Sell	7,491 -1,380	-16%	-$551K	0.21%	34
2020 Q1	$9.13M	Hold	8,871	–	–	0.95%	25
2019 Q4	$11.7M	Buy	8,871 +2,265	+34%	+$3.19M	1.02%	24
2019 Q3	$9.16M	Hold	6,606	–	–	0.84%	30
2019 Q2	$14.9M	Hold	6,606	–	–	1.65%	17
2019 Q1	$19.3M	Hold	6,606	–	–	1.91%	20
2018 Q4	$10.2M	Buy	+6,606	New	+$13.6M	1.29%	24

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Great Point Partners's TPST Position: Q1 2021 in Review

Great Point Partners sold out of Tempest Therapeutics (TPST) in Q1 2021, closing a stake of 1,385 shares — an estimated $578K sold.

Great Point Partners first reported a position in TPST in Q4 2018 and held it in 9 quarters. The position peaked at $19.3M in Q1 2019. 30 funds tracked by Wall St. Rank hold TPST as of Q1 2021.

Great Point Partners reported no remaining Tempest Therapeutics position as of Q1 2021 after selling out during the quarter.
Great Point Partners sold 1,385 Tempest Therapeutics shares in Q1 2021, an estimated $578K.
Great Point Partners first reported a position in Tempest Therapeutics in Q4 2018 and held it in 9 quarters.
Great Point Partners's Tempest Therapeutics position peaked at $19.3M in Q1 2019.
30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2021.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.